Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
10 2019
Historique:
received: 28 12 2018
revised: 08 05 2019
accepted: 31 05 2019
pubmed: 14 6 2019
medline: 15 12 2020
entrez: 14 6 2019
Statut: ppublish

Résumé

The ubiquitin ligase F-box and WD repeat domain-containing 7 (FBXW7) is recognized as a tumor suppressor in many cancer types due to its ability to promote the degradation of numerous oncogenic target proteins. Herein, we aimed to elucidate its role in intrahepatic cholangiocarcinoma (iCCA). Herein, we first confirmed that FBXW7 gene expression was reduced in human iCCA specimens. To identify the molecular mechanisms by which FBXW7 dysfunction promotes cholangiocarcinogenesis, we generated a mouse model by hydrodynamic tail vein injection of Fbxw7ΔF, a dominant negative form of Fbxw7, either alone or in association with an activated/myristylated form of AKT (myr-AKT). We then confirmed the role of c-MYC in human iCCA cell lines and its relationship to FBXW7 expression in human iCCA specimens. FBXW7 mRNA expression is almost ubiquitously downregulated in human iCCA specimens. While forced overexpression of Fbxw7ΔF alone did not induce any appreciable abnormality in the mouse liver, co-expression with AKT triggered cholangiocarcinogenesis and mice had to be euthanized by 15 weeks post-injection. At the molecular level, a strong induction of Fbxw7 canonical targets, including Yap, Notch2, and c-Myc oncoproteins, was detected. However, only c-MYC was consistently confirmed as a FBXW7 target in human CCA cell lines. Most importantly, selected ablation of c-Myc completely impaired iCCA formation in AKT/Fbxw7ΔF mice, whereas deletion of either Yap or Notch2 only delayed tumorigenesis in the same model. In human iCCA specimens, an inverse correlation between the expression levels of FBXW7 and c-MYC transcriptional activity was observed. Downregulation of FBXW7 is ubiquitous in human iCCA and cooperates with AKT to induce cholangiocarcinogenesis in mice via c-Myc-dependent mechanisms. Targeting c-MYC might represent an innovative therapy against iCCA exhibiting low FBXW7 expression. There is mounting evidence that FBXW7 functions as a tumor suppressor in many cancer types, including intrahepatic cholangiocarcinoma, through its ability to promote the degradation of numerous oncoproteins. Herein, we have shown that the low expression of FBXW7 is ubiquitous in human cholangiocarcinoma specimens. This low expression is correlated with increased c-MYC activity, leading to tumorigenesis. Our findings suggest that targeting c-MYC might be an effective treatment for intrahepatic cholangiocarcinoma.

Sections du résumé

BACKGROUND & AIMS
The ubiquitin ligase F-box and WD repeat domain-containing 7 (FBXW7) is recognized as a tumor suppressor in many cancer types due to its ability to promote the degradation of numerous oncogenic target proteins. Herein, we aimed to elucidate its role in intrahepatic cholangiocarcinoma (iCCA).
METHODS
Herein, we first confirmed that FBXW7 gene expression was reduced in human iCCA specimens. To identify the molecular mechanisms by which FBXW7 dysfunction promotes cholangiocarcinogenesis, we generated a mouse model by hydrodynamic tail vein injection of Fbxw7ΔF, a dominant negative form of Fbxw7, either alone or in association with an activated/myristylated form of AKT (myr-AKT). We then confirmed the role of c-MYC in human iCCA cell lines and its relationship to FBXW7 expression in human iCCA specimens.
RESULTS
FBXW7 mRNA expression is almost ubiquitously downregulated in human iCCA specimens. While forced overexpression of Fbxw7ΔF alone did not induce any appreciable abnormality in the mouse liver, co-expression with AKT triggered cholangiocarcinogenesis and mice had to be euthanized by 15 weeks post-injection. At the molecular level, a strong induction of Fbxw7 canonical targets, including Yap, Notch2, and c-Myc oncoproteins, was detected. However, only c-MYC was consistently confirmed as a FBXW7 target in human CCA cell lines. Most importantly, selected ablation of c-Myc completely impaired iCCA formation in AKT/Fbxw7ΔF mice, whereas deletion of either Yap or Notch2 only delayed tumorigenesis in the same model. In human iCCA specimens, an inverse correlation between the expression levels of FBXW7 and c-MYC transcriptional activity was observed.
CONCLUSIONS
Downregulation of FBXW7 is ubiquitous in human iCCA and cooperates with AKT to induce cholangiocarcinogenesis in mice via c-Myc-dependent mechanisms. Targeting c-MYC might represent an innovative therapy against iCCA exhibiting low FBXW7 expression.
LAY SUMMARY
There is mounting evidence that FBXW7 functions as a tumor suppressor in many cancer types, including intrahepatic cholangiocarcinoma, through its ability to promote the degradation of numerous oncoproteins. Herein, we have shown that the low expression of FBXW7 is ubiquitous in human cholangiocarcinoma specimens. This low expression is correlated with increased c-MYC activity, leading to tumorigenesis. Our findings suggest that targeting c-MYC might be an effective treatment for intrahepatic cholangiocarcinoma.

Identifiants

pubmed: 31195063
pii: S0168-8278(19)30342-3
doi: 10.1016/j.jhep.2019.05.027
pmc: PMC6773530
mid: NIHMS1531500
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Cell Cycle Proteins 0
F-Box-WD Repeat-Containing Protein 7 0
Fbxw7 protein, mouse 0
Myc protein, mouse 0
Notch2 protein, mouse 0
Proto-Oncogene Proteins c-myc 0
Receptor, Notch2 0
YAP-Signaling Proteins 0
Yap1 protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

742-752

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026743
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190606
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204586
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228483
Pays : United States

Informations de copyright

Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Références

Curr Cancer Drug Targets. 2015;15(1):53-70
pubmed: 25564254
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460
pubmed: 28844952
J Pathol. 2003 Dec;201(4):589-95
pubmed: 14648662
EMBO J. 2004 May 19;23(10):2116-25
pubmed: 15103331
Cell. 2013 Jun 20;153(7):1552-66
pubmed: 23791182
Semin Liver Dis. 2013 Aug;33(3):248-61
pubmed: 23943105
World J Gastroenterol. 2007 Dec 28;13(48):6470-7
pubmed: 18161916
Eur J Cancer. 2006 Sep;42(14):2369-73
pubmed: 16824748
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Oncogene. 2017 Sep 7;36(36):5087-5097
pubmed: 28481866
Cancer Res. 2007 Jun 15;67(12):5611-6
pubmed: 17575125
Hepatol Res. 2014 Dec;44(14):E346-52
pubmed: 24552289
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):674-8
pubmed: 7904757
Cell Death Dis. 2016 Jun 02;7(6):e2252
pubmed: 27253416
Genes Genet Syst. 2008 Aug;83(4):347-52
pubmed: 18931460
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6584-9
pubmed: 18451027
Cancer Res. 2002 Aug 15;62(16):4535-9
pubmed: 12183400
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
J Hepatobiliary Pancreat Surg. 2001;8(2):154-7
pubmed: 11455472
Surgery. 2013 Jun;153(6):811-8
pubmed: 23499016
Oncogene. 2018 Jun;37(24):3229-3242
pubmed: 29545603
J Clin Invest. 2017 Jan 3;127(1):137-152
pubmed: 27869648
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Biochem Biophys Res Commun. 2008 Dec 12;377(2):685-688
pubmed: 18938137
Epigenetics. 2016 Nov;11(11):780-790
pubmed: 27593557
Medicine (Baltimore). 2016 Feb;95(7):e2496
pubmed: 26886596
Oncogene. 2013 Apr 11;32(15):1921-32
pubmed: 22665065
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncol Lett. 2017 May;13(5):3653-3661
pubmed: 28521468
Oncotarget. 2015 Mar 20;6(8):6310-25
pubmed: 25749036
Cancer Res. 2007 Oct 1;67(19):9006-12
pubmed: 17909001
Oncol Rep. 2017 Mar;37(3):1627-1636
pubmed: 28184929
J Gastroenterol Hepatol. 2014 Oct;29(10):1822-9
pubmed: 24731221
Gastroenterology. 2011 Mar;140(3):1071-83
pubmed: 21147110
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
PLoS One. 2012;7(11):e49453
pubmed: 23166673
Mol Cancer. 2018 Aug 7;17(1):115
pubmed: 30086763
Science. 2008 Sep 12;321(5895):1499-502
pubmed: 18787170
J Natl Cancer Inst. 2014 May 16;106(6):dju107
pubmed: 24838835
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8826-31
pubmed: 24879440
Mol Cancer. 2014 May 17;13:110
pubmed: 24884509
Gastroenterology. 2017 Mar;152(4):745-761
pubmed: 28043904
Neoplasia. 2016 Nov;18(11):666-673
pubmed: 27764699
J Hepatol. 2012 Apr;56(4):848-54
pubmed: 22173164
Oncotarget. 2015 Jul 10;6(19):17206-20
pubmed: 26015398
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
PLoS One. 2013 Jul 01;8(7):e68574
pubmed: 23840897
Epigenomics. 2015;7(3):487-501
pubmed: 26077433

Auteurs

Jingxiao Wang (J)

School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States.

Haichuan Wang (H)

Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.

Michele Peters (M)

Institute of Pathology, University of Greifswald, Greifswald, Germany.

Ning Ding (N)

Department of Gastroenterology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Silvia Ribback (S)

Institute of Pathology, University of Greifswald, Greifswald, Germany.

Kirsten Utpatel (K)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Antonio Cigliano (A)

Institute of Pathology, University of Greifswald, Greifswald, Germany; Institute of Pathology, University of Regensburg, Regensburg, Germany.

Frank Dombrowski (F)

Institute of Pathology, University of Greifswald, Greifswald, Germany.

Meng Xu (M)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States; Department of General Surgery, The Second Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China.

Xinyan Chen (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States; Department of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.

Xinhua Song (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States.

Li Che (L)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States.

Matthias Evert (M)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Antonio Cossu (A)

Unit of Pathology, Azienda Ospedaliero Universitaria Sassari, Sassari, Italy.

John Gordan (J)

Department of Medicine, University of California, San Francisco, CA, United States.

Yong Zeng (Y)

Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China. Electronic address: zengyong@medmail.com.cn.

Xin Chen (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, United States. Electronic address: xin.chen@ucsf.edu.

Diego F Calvisi (DF)

Institute of Pathology, University of Greifswald, Greifswald, Germany; Institute of Pathology, University of Regensburg, Regensburg, Germany. Electronic address: diego.calvisi@klinik.uni-regensburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH